“A major factor contributing to the increase in drug spending is usually the list cost of prescription drugs. Drug manufacturers alone set the list cost of prescription drugs,” said William Fleming, president of health-care services at Humana. “Drug manufacturers raise list prices to boost their revenue.”
High drug costs have become a rare bipartisan issue. President Donald Trump has made lowering prices one of the key issues of his administration, while Democrats are jockeying to prove they can lead reform. PBMs have arguably received the brunt of the blame via lawmakers.
The hearing Tuesday, led by Chairman Chuck Grassley, R-Iowa., along with Ranking Democrat Ron Wyden of Oregon, marks the committee’s third on drug prices This kind of year. In late February, the committee heard testimony via drug executives of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer along with Sanofi.
The pharma executives at the time didn’t talk much about list prices. Instead, they blamed middlemen for pocketing discounts instead of passing them along to patients. They suggested adjustments to Medicare, including capping the amount seniors would certainly pay for on their own at the pharmacy counter every year.
“Pharmaceutical manufacturers insist in which drug cost increases are driven by rebates. This kind of is usually simply not true,” CVS Health Executive Vice President Derica Rice said in his written testimony.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in brand-new York City on May 21.
However, lawmakers grilled the executives for their companies’ alleged roles in rising drug costs.
“Today the committee will be told a thousand different versions of the same talking point: ‘We’re all about getting the best possible cost for patients,'” Wyden said Tuesday. “nevertheless there won’t be actual proof. Bottom line, PBMs are middlemen who strike deals with drugmakers in secret. In my experience, in which kind of negotiation rarely results in an act of charity for consumers.”
Though PBMs are targeted by critics for their rebate system, two of the companies testifying Tuesday have business versions in which don’t benefit via earning high percentages of negotiated rebates.
Prime Therapeutics, which is usually right now owned by 18 Blue Cross insurance plans, negotiates rebates, nevertheless charges a flat administrative fee instead of taking a percentage of the discount. Though Humana takes a percentage of rebates, This kind of only manages pharmacy benefits for its own customers.
The PBM executives suggested Tuesday numerous solutions they believe will lower drug prices, mainly targeting anti-competitive behavior.
They attacked “pay for delay” tactics, which are used by brand-name drugmakers to prevent generic manufacturers via introducing their products to the market by paying them to delay their rollout.
The PBMs voiced support for a bill introduced by Sen. Patrick Leahy, D-Vt., which aims to reduce costs along with increase competitiveness inside pharmaceutical market by stopping drugmakers via withholding samples of their medicines via generic manufacturers.
The executives also targeted strategies used by drugmakers to extend patents. They denounced “evergreening” tactics, in which manufactures make minor adjustments to their medications to lengthen the amount of time their product is usually patented, along with called for reducing the exclusivity period for brand name along with specialty drugs.
WATCH: Expect fiery hearing on role of pharmacy middle men in drug pricing